dimercaprol Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dimercaprol (2, 3-dimercapto-1-propanol) or British anti-Lewisite (BAL), is a colorless or almost colorless liquid chelating agent having a disagreeable, mercaptan-like odor. Dimercaprol was developed at Oxford University during World War II as a means of treating and reversing poisoning from Lewisite, an arsenical gas used in chemical warfare (and thus initially called British anti-Lewisite [BAL]). The sulfhydryl groups of dimercaprol form complexes with certain heavy metals thus preventing or reversing the metallic binding of sulfhydryl-containing enzymes. Parenterally administered dimercaprol is used to treat arsenic, gold, copper and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with edetate clcium disodium. Dimercaprol is occasionally used in the initial treatment of severe, symptomatic Wilson disease, but generally for a short time only.   NCATS

Chemistry

  • SMILES: OCC(S)CS
  • InChIKey: WQABCVAJNWAXTE-UHFFFAOYSA-N
  • Mol. Mass: 124.225
  • ALogP: 0.21
  • ChEMBL Molecule:
    dimercaprol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$58.3560
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,2-dimercapto-3-propanol | 1,2-dithioglycerol | 2,3-dimercapro | 2,3-dimercapto-1-propanol | 2,3-dimercaptol-1-propanol | 2,3-dimercaptopropanol | 2,3-dithiopropanol | 2,3-mercaptopropan-1-ol | 2,3-mercaptopropanol | 3-hydroxy-1,2-propanedithiol | alpha,beta-dithioglycerol | anti-lewisite | bal | b.a.l. | british antilewisite | british anti-lewisite | dicaptol | dimercaprol | dimercaprolum | dimercaptopropanol | dithioglycerine | dithioglycerol | sulfactin

Organizations (3)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (5)


 

Arsenic Poisoning (approved 1946)

Hepatolenticular Degeneration

Lead Poisoning (approved 1946)

Mercury Poisoning (approved 1946)

Poisoning (approved 1946)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue